Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplaston A10 and AS2-1 in Incurable Prostate Cancer
NCT00003516Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1996
- Primary completion
- Mar 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in prostate adenocarcinoma, sponsored by Burzynski Research Institute. Started Mar 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT00003516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003516.